Table 1.
Clinical characteristics of groups of patients.
| Characteristics | Acute Stage of COVID-19 (Favorable Outcome) n = 25 |
Acute Stage of COVID-19 (Unfavorable Outcome) n = 8 |
COVID-19 Survivors n = 33 |
p |
|---|---|---|---|---|
| Female | 14/56.0% | 6/75.0% | 18/54.55% |
p1 = 0.751 p2 = 1.000 p3 < 0.001 |
| Male | 11/44.0% | 2/25.0% | 15/45.45% |
p1 = 0.700 p2 = 1.000 p3 = 0.707 |
| Mean age | 60 56.0–63.0 |
70 62.3–73.3 |
63 52.5–68.5 |
p1 = 0.989 p2 = 0.994 p3 = 0.875 |
| Age group | ||||
| <45 | 3/12.0% | 1/12.5% | 5/15.15% |
p1 = 1.000 p2 = 1.000 p3 = 1.000 |
| 45–59 | 15/60.0% | 1/12.5% | 18/54.55% |
p1 = 0.238 p2 = 0.830 p3 = 0.249 |
| ≥ 60 | 7/28.0% | 6/75.0% | 10/30.3% |
p1 = 0.171 p2 = 1.000 p3 = 0.183 |
| Severity | ||||
| Moderate | 7/28.0% | 0/0% | 16/48.48% |
p1 = 0.309 p2 = 0.325 p3 = 0.090 |
| Severe | 17/68.0% | 1/12.5% | 17/51.52% |
p1 = 0.012 p2 = 0.007 p3 = 0.413 |
| Extremely Severe | 1/4% | 7/87.5% | 0/0% |
p1 < 0.001 p2 = 1.000 p3 = 0.001 |
| Complications | ||||
| Pneumonia | 22/88.0% | 8/100% | 32/96.67% |
p1 = 0.989 p2 = 0.994 p3 = 0.875 |
| Data of CT scan 3–4 | 1/4.0% | 8/100% | 0/0% |
p1 < 0.001 p2 = 0.431 p3 < 0.001 |
| Respiratory failure | 12/48.0% | 8/100% | 14/42.42% |
p1 = 0.355 p2 = 0.816 p3 = 0.224 |
| Systemic inflammatory response syndrome | 5/20.0% | 6/75.0% | 9/27.27% |
p1 = 0.132 p2 = 0.765 p3 = 0.165 |
| Multiple organ failure | 2/8.0% | 3/37.5% | 4/12.1% |
p1 = 0.078 p2 = 0.690 p3 = 0.120 |
| Septic shock | 0/0% | 1/12,5% | 0/0% |
p1 = 0.242 p2 = 1.000 p3 = 0.195 |
| Several complications | 13/52.0% | 8/100% | 15/45.45% |
p1 = 0.363 p2 = 0.819 p3 = 0.232 |
| Concomitant disorders including | ||||
| Hypertension | 10/40.0% | 5 | 27/81.82% |
p1 = 0.509 p2 = 0.131 p3 = 0.764 |
| Diabetes | 2/8.0% | 3 | 5/15.15% |
p1 = 0.134 p2 = 0.690 p3 = 0.355 |
| Cardiovascular diseases | 3/12.0% | 4 | 8/24.24% |
p1 = 0.168 p2 = 0.505 p3 = 0.434 |
| Chronic kidney disease | 0/0% | 2/25.0% | 1/3.03% |
p1 = 0.076 p2 = 1.000 p3 = 0.125 |
| Chronic pulmonary disease | 1/4.0% | 2/25.0% | 2/6.06% |
p1 = 0.181 p2 = 0.818 p3 = 0.209 |
| Chronic liver disease | 0/0% | 2/25.0% | 2/6.06% |
p1 = 0.076 p2 = 0.506 p3 = 0.209 |
| Other disorders | 2/8.0% | 2/25.0% | 3/9.09% |
p1 = 0.291 p2 = 1.000 p3 = 0.295 |
| Several disorders | 15/60.0% | 8/100% | 18/54.55% |
p1 = 0.549 p2 = 0.830 p3 = 0.380 |
| CT scan findings | ||||
| CT1 | 9/36.0% | 0/0% | 17/51.52% |
p1 = 0.168 p2 = 0.631 p3 = 0.090 |
| CT2 | 15/60.0% | 0/0% | 12/36.36% |
p1 = 0.044 p2 = 0.353 p3 = 0.175 |
| CT3 | 1/4.0% | 1/12.5% | 3/9.09% |
p1 = 0.454 p2 = 0.633 p3 = 1.000 |
| CT4 | 0/0% | 7/87.5% | 0/0% |
p1 < 0.001 p2 = 1.000 p3 < 0.001 |
Note: p1—statistically significant differences between patients in the acute stage of COVID-19 with favorable and poor outcomes; p2—statistically significant differences between patients in the acute stage of COVID-19 with favorable outcomes and COVID-19 survivors; p3—statistically significant differences between patients in the acute stage of COVID-19 with poor outcome and COVID-19 survivors.